ATE521608T1 - Glucokinaseaktivatoren - Google Patents
GlucokinaseaktivatorenInfo
- Publication number
- ATE521608T1 ATE521608T1 AT06826456T AT06826456T ATE521608T1 AT E521608 T1 ATE521608 T1 AT E521608T1 AT 06826456 T AT06826456 T AT 06826456T AT 06826456 T AT06826456 T AT 06826456T AT E521608 T1 ATE521608 T1 AT E521608T1
- Authority
- AT
- Austria
- Prior art keywords
- glucokinase
- glucokinase activators
- underactivity
- diseases
- prevention
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title abstract 4
- 108010021582 Glucokinase Proteins 0.000 title abstract 4
- 239000012190 activator Substances 0.000 title 1
- 206010011953 Decreased activity Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73203705P | 2005-11-01 | 2005-11-01 | |
| PCT/US2006/041251 WO2007053345A1 (en) | 2005-11-01 | 2006-10-24 | Glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521608T1 true ATE521608T1 (de) | 2011-09-15 |
Family
ID=37685330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06826456T ATE521608T1 (de) | 2005-11-01 | 2006-10-24 | Glucokinaseaktivatoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8933077B2 (de) |
| EP (1) | EP1948652B1 (de) |
| JP (1) | JP5137207B2 (de) |
| AT (1) | ATE521608T1 (de) |
| AU (1) | AU2006309173B2 (de) |
| CA (1) | CA2628274A1 (de) |
| ES (1) | ES2372540T3 (de) |
| NZ (1) | NZ567858A (de) |
| WO (1) | WO2007053345A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1785420A1 (de) * | 2005-11-14 | 2007-05-16 | 4Sc Ag | Thiazolanalogen und ihre Verwendung |
| EP2061767B1 (de) | 2006-08-08 | 2014-12-17 | Sanofi | Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung |
| CA2681695A1 (en) * | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2573087A1 (de) | 2007-09-21 | 2013-03-27 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1,2,4-thiadiazol Derivate als glucokinase Activatoren zur Behandlung von Diabetes Mellitus |
| BRPI0818658A2 (pt) | 2007-10-09 | 2015-04-14 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de piridina úteis como ativadores de glicoquinase |
| KR101133772B1 (ko) | 2007-12-20 | 2012-04-24 | 주식회사 엘지생명과학 | 글루코키나아제 활성화제 및 이를 활성성분으로 함유하는 약제학적 조성물 |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| EP2408769A1 (de) * | 2009-03-17 | 2012-01-25 | Glaxo Group Limited | Als itk-inhibitoren verwendete pyrimidinderivate |
| CN102639537B (zh) * | 2009-07-10 | 2015-07-22 | 拜耳知识产权有限责任公司 | 吲唑基取代的二氢异*唑并吡啶及其使用方法 |
| KR20120060207A (ko) | 2009-08-26 | 2012-06-11 | 사노피 | 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도 |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| JPWO2012121314A1 (ja) | 2011-03-09 | 2014-07-17 | 第一三共株式会社 | ジピリジルアミン誘導体 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2804605A4 (de) * | 2012-01-20 | 2015-07-08 | Acucela Inc | Substituierte heterocyclische verbindungen zur behandlung von krankheiten |
| CA2877026A1 (en) | 2012-05-18 | 2013-11-21 | Amgen Inc. | Method for the preparation of thiadiazoles |
| WO2019084529A1 (en) * | 2017-10-29 | 2019-05-02 | China Medical University | ADAM9 INHIBITORS AND USES THEREOF |
| AU2019318209B2 (en) | 2018-08-10 | 2025-09-25 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
| EP1169038B9 (de) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclische protein-tyrosinkinasehemmer |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| AU779908B2 (en) * | 1999-09-10 | 2005-02-17 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| NZ540791A (en) * | 2003-02-13 | 2009-09-25 | Banyu Pharma Co Ltd | Novel 2-pyridinecarboxamide derivatives |
| US7687502B2 (en) * | 2004-03-23 | 2010-03-30 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
-
2006
- 2006-10-24 NZ NZ567858A patent/NZ567858A/en not_active IP Right Cessation
- 2006-10-24 JP JP2008538915A patent/JP5137207B2/ja not_active Expired - Fee Related
- 2006-10-24 WO PCT/US2006/041251 patent/WO2007053345A1/en not_active Ceased
- 2006-10-24 US US12/092,233 patent/US8933077B2/en not_active Expired - Fee Related
- 2006-10-24 CA CA002628274A patent/CA2628274A1/en not_active Abandoned
- 2006-10-24 AU AU2006309173A patent/AU2006309173B2/en not_active Ceased
- 2006-10-24 AT AT06826456T patent/ATE521608T1/de not_active IP Right Cessation
- 2006-10-24 ES ES06826456T patent/ES2372540T3/es active Active
- 2006-10-24 EP EP06826456A patent/EP1948652B1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007053345A1 (en) | 2007-05-10 |
| US8933077B2 (en) | 2015-01-13 |
| AU2006309173A1 (en) | 2007-05-10 |
| EP1948652A1 (de) | 2008-07-30 |
| EP1948652B1 (de) | 2011-08-24 |
| CA2628274A1 (en) | 2007-05-10 |
| US20100056530A1 (en) | 2010-03-04 |
| ES2372540T3 (es) | 2012-01-23 |
| NZ567858A (en) | 2011-08-26 |
| JP2009513700A (ja) | 2009-04-02 |
| AU2006309173B2 (en) | 2011-08-18 |
| JP5137207B2 (ja) | 2013-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| SG170775A1 (en) | 2 -aminopyridine analogs as glucokinase activators | |
| TW200740804A (en) | Glucokinase activators | |
| WO2008118718A3 (en) | 2-aminopyridine analogs as glucokinase activators | |
| CR11383A (es) | Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus | |
| NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
| ATE435015T1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
| WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| MX2007007409A (es) | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. | |
| EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
| GB0402137D0 (en) | Novel compounds | |
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
| GB0402143D0 (en) | Novel compounds | |
| MX2007005590A (es) | Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas. | |
| WO2007041365A3 (en) | 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| ATE552000T1 (de) | Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| ATE534649T1 (de) | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |